Literature DB >> 2168984

Activity of herpes simplex virus type 1 latency-associated transcript (LAT) promoter in neuron-derived cells: evidence for neuron specificity and for a large LAT transcript.

J C Zwaagstra1, H Ghiasi, S M Slanina, A B Nesburn, S C Wheatley, K Lillycrop, J Wood, D S Latchman, K Patel, S L Wechsler.   

Abstract

By using chloramphenicol acetyltransferase (CAT) assays in neuron-derived cell lines, we show here that promoter activity associated with the herpes simplex virus type 1 latency-associated transcript (LAT) had neuronal specificity. Promoter activity in these transient CAT assays coincided with a DNA region containing excellent RNA polymerase II promoter consensus sequences. Primer extension analysis in a LAT promoter-CAT plasmid construct placed the start of transcription about 28 nucleotides from the first T in the consensus TATA box sequence. Neuronal specificity of this promoter was suggested by examining the effect of sequences upstream of the promoter on CAT activity in neuronal versus nonneuronal cells. In nonneuronal cells, promoter activity was decreased 3- to 12-fold with the addition of upstream sequences. In contrast, in neuron-derived cells, the addition of upstream sequences did not decrease promoter activity. The LAT promoter predicted by our transient CAT assays was located over 660 nucleotides upstream from the 5' end of the previously mapped 2-kilobase (kb) LAT. This unusual location was explained by in situ and Northern (RNA) blot hybridization analyses that suggested that LAT transcription began near the promoter detected in our CAT assays, rather than near the 5' end of the 2-kb LAT. In situ hybridization with neurons from latently infected rabbits detected small amounts of LAT RNA within 30 nucleotides of the consensus TATA box sequence. This suggested that LAT transcription began near this TATA box. Northern blot hybridization of RNA from ganglia of latently infected rabbits revealed a faint 8.3-kb band of the same sense as LAT. We conclude that (i) the LAT promoter has neuronal specificity, (ii) the LAT promoter is located over 660 nucleotides upstream of the 5' end of the previously characterized stable 2-kb LAT, (iii) LAT transcription begins about 28 nucleotides from the first T of the consensus TATA box sequence and extends to near the first available polyadenylation site approximately 8.3 kb away, and (iv) this 8.3-kb RNA may be an unstable precursor of the more stable 2- and 1.3-kb LATs.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2168984      PMCID: PMC247993          DOI: 10.1128/JVI.64.10.5019-5028.1990

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  Herpes simplex virus latent RNA (LAT) is not required for latent infection in the mouse.

Authors:  D Y Ho; E S Mocarski
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

Review 2.  LATENT HERPES SIMPLEX INFECTION IN MAN.

Authors:  T F PAINE
Journal:  Bacteriol Rev       Date:  1964-12

3.  In vitro promoter activity associated with the latency-associated transcript gene of herpes simplex virus type 1.

Authors:  J Zwaagstra; H Ghiasi; A B Nesburn; S L Wechsler
Journal:  J Gen Virol       Date:  1989-08       Impact factor: 3.891

4.  Sequence of the latency-related gene of herpes simplex virus type 1.

Authors:  S L Wechsler; A B Nesburn; J Zwaagstra; H Ghiasi
Journal:  Virology       Date:  1989-01       Impact factor: 3.616

5.  Identification of the latency-associated transcript promoter by expression of rabbit beta-globin mRNA in mouse sensory nerve ganglia latently infected with a recombinant herpes simplex virus.

Authors:  A T Dobson; F Sederati; G Devi-Rao; W M Flanagan; M J Farrell; J G Stevens; E K Wagner; L T Feldman
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

6.  Spontaneous reactivation of experimental herpes simplex keratitis in rabbits.

Authors:  A B Nesburn; J H Elliott; H M Leibowitz
Journal:  Arch Ophthalmol       Date:  1967-10

7.  A herpes simplex virus type 1 variant, deleted in the promoter region of the latency-associated transcripts, does not produce any detectable minor RNA species during latency in the mouse trigeminal ganglion.

Authors:  W J Mitchell; I Steiner; S M Brown; A R MacLean; J H Subak-Sharpe; N W Fraser
Journal:  J Gen Virol       Date:  1990-04       Impact factor: 3.891

8.  Mapping of low abundance latency-associated RNA in the trigeminal ganglia of mice latently infected with herpes simplex virus type 1.

Authors:  W J Mitchell; R P Lirette; N W Fraser
Journal:  J Gen Virol       Date:  1990-01       Impact factor: 3.891

9.  A herpes simplex virus type 1 latency-associated transcript mutant reactivates with normal kinetics from latent infection.

Authors:  T M Block; J G Spivack; I Steiner; S Deshmane; M T McIntosh; R P Lirette; N W Fraser
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

10.  Herpes simplex virus type 1 latency-associated transcripts are evidently not essential for latent infection.

Authors:  I Steiner; J G Spivack; R P Lirette; S M Brown; A R MacLean; J H Subak-Sharpe; N W Fraser
Journal:  EMBO J       Date:  1989-02       Impact factor: 11.598

View more
  111 in total

1.  Enhancer and long-term expression functions of herpes simplex virus type 1 latency-associated promoter are both located in the same region.

Authors:  H Berthomme; J Thomas; P Texier; A Epstein; L T Feldman
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Neither LAT nor open reading frame P mutations increase expression of spliced or intron-containing ICP0 transcripts in mouse ganglia latently infected with herpes simplex virus.

Authors:  Shun-Hua Chen; Lily Yeh Lee; David A Garber; Priscilla A Schaffer; David M Knipe; Donald M Coen
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

3.  The stable 2.0-kilobase intron of the herpes simplex virus type 1 latency-associated transcript does not function as an antisense repressor of ICP0 in nonneuronal cells.

Authors:  Edward A Burton; Chang-Sook Hong; Joseph C Glorioso
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

Review 4.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

5.  Analysis of individual human trigeminal ganglia for latent herpes simplex virus type 1 and varicella-zoster virus nucleic acids using real-time PCR.

Authors:  R J Cohrs; J Randall; J Smith; D H Gilden; C Dabrowski; H van Der Keyl; R Tal-Singer
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 6.  Herpes simplex virus latency-associated transcript gene function.

Authors:  Jennifer R Kent; Wen Kang; Cathie G Miller; Nigel W Fraser
Journal:  J Neurovirol       Date:  2003-06       Impact factor: 2.643

7.  Localization of cis-acting sequence requirements in the promoter of the latency-associated transcript of herpes simplex virus type 1 required for cell-type-specific activity.

Authors:  A H Batchelor; P O'Hare
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

8.  Optic neuritis in different strains of mice by a recombinant HSV-1 expressing murine interleukin-2.

Authors:  Mandana Zandian; Raelene Belisle; Kevin R Mott; Steven Nusinowitz; Florence M Hofman; Homayon Ghiasi
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-02-21       Impact factor: 4.799

9.  Two open reading frames (ORF1 and ORF2) within the 2.0-kilobase latency-associated transcript of herpes simplex virus type 1 are not essential for reactivation from latency.

Authors:  M U Fareed; J G Spivack
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

10.  The latency-associated transcript gene of herpes simplex virus type 1 (HSV-1) is required for efficient in vivo spontaneous reactivation of HSV-1 from latency.

Authors:  G C Perng; E C Dunkel; P A Geary; S M Slanina; H Ghiasi; R Kaiwar; A B Nesburn; S L Wechsler
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.